Earlobe sarcoidosis

Adriane Dore Marie Vorselaars*, R. G.M. Keijsers, J. C. Grutters

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

Background: Infliximab, a TNF-α blocking agent, is an upcoming therapeutic option for cases of refractory sarcoidosis. In pulmonary sarcoidosis, changes imaged by 18F-FDG-PET during infliximab treatment in sarcoidosis patients correlate with signs of clinical improvement. Design: Case-report. Results and conclusions: A patient with severe earlobe sarcoidosis, treated with infliximab, is presented. This case shows that even relatively small extrapulmonary localisations of sarcoidosis can be visualised by 18F-FDG-PET, and that a decrease of FDG-uptake correlates well with clinical improvement on infliximab treatment.

Original languageEnglish
Pages (from-to)55-57
Number of pages3
JournalSarcoidosis Vasculitis and Diffuse Lung Diseases
Volume29
Issue number1
Publication statusPublished - 2012

Keywords

  • 18F-FDG-PET
  • Infliximab
  • Sarcoidosis
  • TNF-α mAb

Fingerprint

Dive into the research topics of 'Earlobe sarcoidosis'. Together they form a unique fingerprint.

Cite this